


Transformative healthcare shouldn't come at the expense of our planet's health. Our customers – researchers, academia, and biopharma companies – are setting ambitious sustainability targets to tackle our industry's environmental impact.

So we asked **800 biopharma leaders** across the globe: what are they doing to improve sustainability? What obstacles are they facing? And how can the industry as a whole learn from the companies that are leading the way?

Here's what we found:

Sustainability is the number one priority for **62%** of biopharma companies over the next five years.

Over the past 12 months, companies leading in sustainability have experienced **increases in:**



But a lack of ability to accurately measure and manage **Scope 3 emissions** will make or break biopharma's sustainability progress.

Only **17%**

of companies are confident in their ability to accurately measure Scope 3 emissions.

Supplier and industry **cooperation** can trigger systemic change.

69%

of respondents say that weak collaboration across the value chain is a barrier to sustainability.

57%

of companies leading in sustainability are working with suppliers and other stakeholders to campaign for better policy and regulation around sustainability, compared with 47% of late adopters.

Get more insights from the report at cytiva.com/sustainability-review

How is Cytiva helping? Learn more at cytiva.com/sustainability